The estimated Net Worth of Renato Skerlj is at least 76 千$ dollars as of 9 September 2020. Renato Skerlj owns over 5,834 units of X4 Pharmaceuticals stock worth over 29,032$ and over the last 4 years Renato sold XFOR stock worth over 46,964$.
Sign up
Renato Skerlj XFOR stock SEC Form 4 insiders trading
Renato has made over 1 trades of the X4 Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Renato sold 5,834 units of XFOR stock worth 46,964$ on 9 September 2020.
The largest trade Renato's ever made was selling 5,834 units of X4 Pharmaceuticals stock on 9 September 2020 worth over 46,964$. On average, Renato trades about 1,945 units every 0 days since 2020. As of 9 September 2020 Renato still owns at least 42,076 units of X4 Pharmaceuticals stock.
You can see the complete history of Renato Skerlj stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Renato Skerlj's mailing address?
Renato's mailing address filed with the SEC is 12 CROCKER CIRCLE, , NEWTON, MA, 02465.
Insiders trading at X4 Pharmaceuticals
Over the last 6 years, insiders at X4 Pharmaceuticals have traded over 2,179,690$ worth of X4 Pharmaceuticals stock and bought 25,000 units worth 30,000$ . The most active insiders traders include Paula Ragan、Adam S. Mostafa、Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of 12,232$. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth 1,744$.
What does X4 Pharmaceuticals do?
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
What does X4 Pharmaceuticals's logo look like?
Complete history of Renato Skerlj stock trades at X4 Pharmaceuticals
X4 Pharmaceuticals executives and stock owners
X4 Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Paula Ragan,
President, Chief Executive Officer, Corporate Secretary, Director -
Adam Mostafa,
Chief Financial Officer, Treasurer -
Dr. Paula Ragan Ph.D.,
Founder, CEO, Pres, Sec. & Director -
Derek M. Meisner Esq., J.D.,
Chief Legal Officer & Corp. Sec. -
Adam S. Mostafa,
CFO, Treasurer & Assistant Sec. -
Michael Wyzga,
Independent Chairman of the Board -
Gary Bridger,
Independent Director -
Murray Stewart,
Independent Director -
David McGirr,
Independent Director -
William Aliski,
Independent Director -
Rene Russo,
Director -
Candice Ellis,
Director, Corporate Communications & Investor Relations -
Alison Lawton,
Director -
Derek Meisner,
General Counsel -
Arthur Taveras,
Chief Scientific Officer -
Dr. Diego Cadavid M.D.,
Chief Medical Officer -
Carrie Melvin M.B.A.,
Sr. VP of Devel. Operations -
Dr. Robert David Arbeit,
Sr. VP of Clinical Devel. and Translational Research -
Ronny Mosston M.B.A.,
Sr. VP of HR -
Dr. Mary DiBiase Ph.D.,
Chief Operating Officer -
Keith Woods,
Director -
Craecker Francoise De,
Director -
Christophe Arbet Engels,
Chief Medical Officer -
Renato Skerlj,
Chief Scientific Officer -
Lynne E Kelley,
Chief Medical Officer -
Diego Cadavid,
Chief Medical Officer -
Mary Di Biase,
Chief Operating Officer